Fol. Biol. 2013, 59, 116-122
https://doi.org/10.14712/fb2013059030116
The Effects of DPP-IV Inhibition in NOD Mice with Overt Diabetes
References
1. , V., Sherry, N. A., Kushner, J. A., Herold, K. C. (2007) Autoimmunity and β cell regeneration in mouse and human type 1 diabetes: the peace is not enough. Ann. N. Y. Acad. Sci. 1103, 19-32.
<https://doi.org/10.1196/annals.1394.006>
2. , E. (2010) Time for testing incretin therapies in early type 1 diabetes? J. Clin. Endocrinol. Metab. 95, 2607-2609.
<https://doi.org/10.1210/jc.2009-2741>
3. , S. L., Moser, E. G., Snell-Bergeon, J. K., Rodionova, A. S., Hazenfield, R. M., Garg, S. K. (2011) Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet. Med. 28, 1176-1181.
<https://doi.org/10.1111/j.1464-5491.2011.03331.x>
4. , I., Baggio, L. L., Poussier, P., Drucker, D. J. (2008) Exendin-4 modulates diabetes onset in nonobese diabetic mice. Endocrinology 149, 1338-1349.
<https://doi.org/10.1210/en.2007-1137>
5. , H. A., Sun, J. K., Levine, J., Doria, A., Aiello, L. P., Eisenbarth, G., Bonner-Weir, S., King, G. L. (2010) Residual insulin production and pancreatic b-cell turnover after 50 years of diabetes: Joslin Medalist Study. Diabetes 59, 2846-2853.
<https://doi.org/10.2337/db10-0676>
6. , U., Holst, J. J., Madsbad, S. (2011) Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes 60, 1599-1607.
<https://doi.org/10.2337/db10-1790>
7. , S. J., Nian, C., McIntosh, C. H. (2010) Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways. Diabetes 59, 1739-1750.
<https://doi.org/10.2337/db09-1618>
8. , E. (2011) Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series. J. Med. Case Rep. 5, 117.
<https://doi.org/10.1186/1752-1947-5-117>
9. , E., Pala, L., Ciani, S., Bardini, G., Pezzatini, A., Sposato, I., Cremasco, F., Ognibene, A., Rotella, C. M. (2005) Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 48, 1168-1172.
<https://doi.org/10.1007/s00125-005-1749-8>
10. , R. J., Thomas, D., Phillips, J. M., Cooke, A. (2007) Diabetes in non-obese diabetic mice is not associated with quantitative changes in CD4+ CD25+ Foxp3+ regulatory T cells. Immunology 121, 15-28.
<https://doi.org/10.1111/j.1365-2567.2007.02546.x>
11. , N., List, J. F., Habener, J. F., Maki, T. (2004) Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 53, 1700-1705.
<https://doi.org/10.2337/diabetes.53.7.1700>
12. , B. O., Peakman, M. (2012) Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb. Perspect. Med. 2, a007781.
<https://doi.org/10.1101/cshperspect.a007781>
13. , L. K., Young, D. L., Ramanujan, S., Whiting, C. C., Atkinson, M. A., Bluestone, J. A., Eisenbarth, G. S., Mathis, D., Rossini, A. A., Campbell, S. E., Kahn, R., Kreuwel, H. T. (2005) A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23, 115-126.
<https://doi.org/10.1016/j.immuni.2005.08.002>
14. , A., Ellis, R. J., Varela-Calvino, R., Arif, S., Huang, G. C., Van-Krinks, C., Zaremba, A., Rackham, C., Allen, J. S., Tree, T. I., Zhao, M., Dayan, C. M., Sewell, A. K., Unger, W. W., Drijfhout, J. W., Ossendorp, F., Roep, B. O., Peakman, M. (2008) CTLs are targeted to kill β cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J. Clin. Invest. 118, 3390-3402.
15. , W. L., Lakey, J. R., Rabinovitch, A. (2008) Combination therapy with glucagon-like peptide-1 and gastrin induces b-cell neogenesis from pancreatic duct cells in human islets transplanted in immunodeficient diabetic mice. Cell Transplant. 17, 631-640.
<https://doi.org/10.3727/096368908786092775>
16. , W. L., Cembrowski, G. S., Rabinovitch, A. (2009) Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia 52, 1680-1682.
<https://doi.org/10.1007/s00125-009-1390-z>
17. , C. S., Burn, P. (2012) The potential of incretin-based therapies in type 1 diabetes. Drug Discov. Today 17, 89-95.
<https://doi.org/10.1016/j.drudis.2011.08.017>
18. , Y., Fujita, Y., Honjo, J., Yanagimachi, T., Sakagami, H., Takiyama, Y., Makino, Y., Abiko, A., Kieffer, T. J., Haneda, M. (2011) Reduction of both β cell death and α cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. Diabetologia 55, 404-412.
<https://doi.org/10.1007/s00125-011-2365-4>
19. , B., Hao, J., Zhang, Y., Tian, L., Yi, H., O’Brien, T. D., Sutherland, D. E., Hering, B. J., Guo, Z. (2009) Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy. Transplantation 87, 198-206.
<https://doi.org/10.1097/TP.0b013e3181933261>
20. , L., Gao, J., Hao, J., Zhang, Y., Yi, H., O’Brien, T. D., Sorenson, R., Luo, J., Guo, Z. (2010) Reversal of new-onset diabetes through modulating inflammation and stimulating β-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor. Endocrinology 151, 3049-3060.
<https://doi.org/10.1210/en.2010-0068>
21. , S., Wasserfall, C. H., Parker, M., Brusko, T. M., McGrail, S., McGrail, K., Moore, M., Campbell-Thompson, M., Schatz, D. A., Atkinson, M. A., Haller, M. J. (2008) Exendin-4 therapy in NOD mice with new-onset diabetes increases regulatory T cell frequency. Ann. N. Y. Acad. Sci. 1150, 152-156.
<https://doi.org/10.1196/annals.1447.049>
22. , J., Tokui, Y., Yamagata, K., Kozawa, J., Sayama, K., Iwahashi, H., Okita, K., Miuchi, M., Konya, H., Hamaguchi, T., Namba, M., Shimomura, I., Miyagawa, J. I. (2007) Continuous stimulation of human glucagon-like peptide-1 (7-36) amide in a mouse model (NOD) delays onset of autoimmune type 1 diabetes. Diabetologia 50, 1900-1909.
<https://doi.org/10.1007/s00125-007-0737-6>
